Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: William blair - The Real Truth

Appian CFO Says AI Workflows, Government Demand Are Driving Big-Customer Growth

Appian (NASDAQ:APPN) Chief Financial Officer Serge Tanjga said the company is seeing stronger traction with large enterprise and government customers as it positions its low-code automation platform around regulated, mission-critical workflows and embedded artificial intelligence. Speaking at Willi

MarketBeat

Alkami Technology Touts $500M ARR, AI Upside and Bank Demand at Fintech Event

Alkami Technology (NASDAQ:ALKT) executives outlined the company’s growth strategy, financial outlook and market positioning during a William Blair fintech and payments event, emphasizing demand from regional banks and credit unions seeking digital capabilities comparable to large banks and fintechs.

MarketBeat

AAON Sees HVAC Recovery, $1B Data Center Opportunity Despite Margin Pressure

AAON (NASDAQ:AAON) executives outlined expectations for continued growth in both light commercial HVAC and data center markets during a William Blair presentation, while also addressing recent production challenges, margin pressure and ongoing efforts to scale the company’s operations. CEO Matt Tob

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Ignore the Amazon Trucking Noise and Buy UPS Stock for Its High Yield Near 7%

While Amazon’s logistics push is weighing on UPS stock, investors may want to consider the company’s shareholder-friendly approach before writing it off.

Barchart

Is Carvana Stock a Buy on New Stock Split Announcement?

Carvana stock inched up as the company announces 5-for-1 stock split. William Blair continues to recommend buying CVNA shares.

Barchart

Here’s What Options Traders Expect from Palantir Stock After Earnings

Palantir stock has slipped below $150 ahead of its earnings release on Feb. 2. But a William Blair analyst says the trajectory will reverse after the quarterly report later today.

Barchart

Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza

William Blair initiated coverage on Viridian Therapeutics Inc. (NASDAQ:VRDN) on Wednesday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytomegalovirus (CMV) vaccine. CMV is a herpes virus. Those who are pregnant or have compromised immune systems are most at risk from CMV.

Benzinga

Thermo Fisher's Upbeat Earnings Suggest Worst Is Over For Scientific Tools Sector, Analyst Says

Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported third-quarter 2025 adjusted earnings of $5.79 per share, beating the street view of $5.49.

Benzinga

Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans

Kezar Life Sciences, Inc. (NASDAQ:KZR) announced regulatory updates and began exploring strategic alternatives.

Benzinga

Analyst Sees Noise In Q3 P&L, Affirms Abbott's Medtech Strength

Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter on Wednesday and narrowed its fiscal 2025 guidance.

Benzinga

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity

William Blair initiated coverage for Climb Bio (NASDAQ:CLYM), citing the potential of the company’s budoprutug, under development for autoimmune indications, including:

Benzinga

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of approximately $8 billion.

Benzinga

Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline

Dianthus Therapeutics Inc. (NASDAQ:DNTH) released topline data from the Phase 2 MaGic trial evaluating the safety and efficacy of claseprubart (DNTH103) in adults with acetylcholine receptor antibody-positive (AChR+) generalized myasthenia gravis (gMG).

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

On Thursday, Skye Bioscience Inc. (NASDAQ:SKYE) reported positive results from two preclinical obesity studies testing nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody.

Benzinga

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

On Wednesday, Amgen Inc. (NASDAQ:AMGN) and its partner Zai Lab (NASDAQ:ZLAB) said the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) in first-line gastric cancer has been completed.

Benzinga

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Argenx SE (NASDAQ:ARGX) stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab).

Benzinga

CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential

CareDx, Inc. (NASDAQ:CDNA) faces fresh uncertainty as proposed reimbursement changes threaten its core testing business, clouding near-term growth even as the company’s expanding transplant solutions platform positions it for long-term opportunity in an $8 billion market.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

As Zero-Emission Credit Revenue Dries Up, What Does That Mean for Tesla Stock?

As Tesla loses its regulatory credit revenue stream, the company now faces growing pressure to sustain profitability through core operations amid cooling EV demand and intensifying competition.

Benzinga

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

The biotechnology sector is experiencing a surge in innovation as companies develop advanced therapies to address complex diseases. This wave of progress is particularly evident in the development of novel treatments for autoimmune disorders, where cutting-edge cell therapies hold promise to transform patient care.

Benzinga

Thermo Fisher Positioned As Biopharma's Partner Of Choice

Could Thermo Fisher Scientific Inc. (NYSE:TMO) be the unsung hero of the biopharma sector's future? While its stock performance has recently lagged, analysts are betting on a major turnaround driven by strategic acquisitions and robust growth potential. William Blair initiated coverage on Tuesday on Thermo Fisher Scientific, citing a strong…

Benzinga

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Investors appear disappointed with Viking Therapeutics Inc.’s (NASDAQ:VKTX) data from its Phase 2 trial of an obesity pill.

Barchart

As SoFi Launches International Money Transfer Services, How Should You Play SOFI Stock?

SoFi Technologies announced plans to launch an international money transfer service by the end of 2025. Here’s why that could prove a major positive for SOFI stock.

Benzinga

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s recent setback and…

Barchart

Analysts Love This AI Data Center Stock

This data center stock has just received an ‘Outperform’ rating from a major financial firm after posting its quarterly results.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.